ASCO 2017 - Lung Cancer - Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC

Video

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?

Subscribe to dacomitinib